← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #432 OF 1,000 MOST-CITED

Written SE plan not implemented/followed

FDA cited this observation 45 times across 37 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods45
BY FISCAL YEAR
FY20262
FY20256
FY20246
FY20234
FY20222
FY20204
FY201911
FY20185
FY20175

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.2× the rate of the average FDA-cited firm (27.0% vs 8.3%), across 37 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Your written SE prevention plan is not fully implemented and followed.

Ben Mald Corp. · Corozal, Puerto Rico · Foods · 2026-03-13

Your written SE prevention plan is not fully implemented and followed.

National Food NW LLC - Stanwood Farm · Stanwood, Washington · Foods · 2026-02-19

Your written SE prevention plan is not implemented and followed.

Carlyle B. Snyder · Little Falls, New York · Foods · 2025-09-24

Your written SE prevention plan is not implemented and followed.

Country Eggs, LLC · Lucerne Valley, California · Foods · 2025-09-10

Your written SE prevention plan is not fully implemented and followed.

Central Valley Eggs, LLC · Wasco, California · Foods · 2025-08-21

Your written SE prevention plan is not implemented and followed.

Samuel R. Stoltzfus · Ovid, New York · Foods · 2025-03-20

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Food industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →